Like any wellness product, results depend on individual biology and consistency, but following these guidelines maximizes your chances of a positive outcome
By Molecule Class, Semaglutide Leads Today but Cedes Leadership by 2035 Semaglutide holds a commanding 58% share of the obesity GLP-1 market in 2025, underpinned by robust clinical validation from the STEPandSELECT trials, proven cardiovascular benefits, and extensive real-world use
NordicTrack assumes no responsibility for any personal injury or damage sustained by any recommendations, opinions, or advice given in this article
Research has shown that GLP-1s effectively reduce blood glucose in people with type 2 diabetes
Ro published a real-world study in Obesity journal on December 10, 2025
These findings underscore the importance of considering demographic factors when evaluating the safety and efficacy of GLP-1 RAs in clinical practice